Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, today announced that Dr. George Gittes, the lead researcher and Harvard graduate that developed Genprex’s new potentially curative diabetes gene therapy, was featured in a video interview discussing the therapy. According to the update, Dr. Gittes joined one of Proactive’s broadcast journalists to provide an overview of the gene therapy, how it works, how it may have the potential to help treat type 1 and type 2 diabetes, as well as next steps to move the gene therapy to the clinic. “We noticed that by gene therapy we could cause some of the cells in the pancreas that do not normally make insulin, but they are closely related to insulin cells, to turn into an insulin-producing cell,” Dr. Gittes, Co-Scientific Director and Professor of Surgery at the UPMC Children’s Hospital of Pittsburgh, said in the interview. “The real excitement came when we realized that when we did this in a mouse that normally reacts to its own insulin cells in the same way a juvenile diabetic or Type 1 diabetic does, it didn’t notice these [new] cells and left them alone for a long time without us doing anything else. It was just one treatment with a gene therapy, and they [the mice] were fine for months, which is exciting.”
To watch the full video interview, visit: http://nnw.fm/VOm6k
To view the full press release, visit http://nnw.fm/bN3Di
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and other serious diseases who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches for patients with cancer and other serious diseases. The company’s lead product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), uses the company’s unique, proprietary platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. In January 2020, the FDA granted Fast Track Designation for Oncoprex in combination with AstraZeneca’s Tagrisso(R) for the treatment of NSCLC. For more information, please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://nnw.fm/GNPX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.